Mavacamten Redefines Long-Term Outcomes in Obstructive Hypertrophic Cardiomyopathy: 128-Week Results From the VALOR-HCM Trial
Posted inCardiology Internal Medicine news

Mavacamten Redefines Long-Term Outcomes in Obstructive Hypertrophic Cardiomyopathy: 128-Week Results From the VALOR-HCM Trial

The 128-week follow-up of the VALOR-HCM trial demonstrates that mavacamten provides sustained relief from LVOT obstruction, promotes favorable cardiac remodeling, and significantly reduces the need for invasive septal reduction therapy in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Mavacamten Significantly Reduces Myocardial Stress and Injury in Nonobstructive HCM: Insights From the ODYSSEY-HCM Trial
Posted inCardiology news

Mavacamten Significantly Reduces Myocardial Stress and Injury in Nonobstructive HCM: Insights From the ODYSSEY-HCM Trial

While the ODYSSEY-HCM trial missed its primary functional endpoints, a new exploratory analysis reveals that mavacamten significantly reduces NT-proBNP and hs-cTnI levels in patients with nonobstructive hypertrophic cardiomyopathy, suggesting a potent biological effect on myocardial wall stress and chronic injury.
Beyond Peak VO2: VO2T12.5% Emerges as a Cardiospecific Marker of Performance and Therapeutic Response in Obstructive HCM
Posted inCardiology news

Beyond Peak VO2: VO2T12.5% Emerges as a Cardiospecific Marker of Performance and Therapeutic Response in Obstructive HCM

This substudy of the SEQUOIA-HCM trial identifies VO2T12.5% as a novel exercise recovery metric. It uniquely reflects cardiac hemodynamics, predicts clinical outcomes, and demonstrates significant improvement with aficamten therapy, offering a simple yet powerful tool for clinical cardiopulmonary exercise testing.